New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Business Wire
SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential..